Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

nts, short-term investments and net working capital of $5,635,365, $6,825,190 and $9,088,712, respectively. The Company currently believes that it has adequate financial resources to continue into the fourth quarter of fiscal 2008 based on planned research and development expenditures and operating costs.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Financial Information to Follow:

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

INTERIM BALANCE SHEETS

(Unaudited)

-------------------------------------------------------------------------

May 31, November 30,

2008 2007

$ $

-------------------------------------------------------------------------

Assets

Current assets:

Cash and cash equivalents 8,543,124 5,635,365

Short-term investments - 6,825,190

Receivables 185,672 230,126

Refundable tax credits 600,000 400,000

Prepaid expenses
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... This is a professional and in-depth ... Hardener industry in Global and China. The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... Pittcon is pleased to announce that the ... Horiba Scientific, have organized a session on nanotechnology for ... , Asia’s largest analytical and scientific instruments show, will ... , The four speakers in this U.S. symposium, ... to Single Cells” will present their use of nanotechnology ...
Breaking Biology Technology:Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Authentication ... This presentation identifies key challenges facing manufacturers of ... technology is being leveraged to overcome ... that enhances safety and reliability, increases revenue and brand ...
... 11 , - TB-402 Shows Clear Promise ... Thromboembolic Disorders., ThromboGenics NV (Euronext Brussels:THR), a ... that the results of the,first Phase I trial ... Society of Hematology (ASH) 49th Annual Meeting in ...
... TTG ), a leading manufacturer of sterile biological implant ... results for the fiscal year and fourth quarter ended September,30, ... fiscal year include:, -- Total fiscal year 2007 ... increased 38% in fiscal year 2007; -- Sales ...
Cached Biology Technology:SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
(Date:8/29/2014)... fold them: modern materials that are light, flexible and ... skin or electronic paper. , Making such concepts affordable ... new way of working with copper nanowires and a ... Previous success in the field of ultra-lightweight "aerogel monoliths" ... and silver nanowires. , By turning instead to ...
(Date:8/28/2014)... called TX Invasives is now available from the Lady ... at Austin for identifying harmful non-native plant, insect and ... the United States cause about $137 billion in economic ... clog waterways, kill native plants and more. , "By ... reporting where invasive species occur, we,re more likely to ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Copper shines as flexible conductor 2Mobile app makes ID of harmful plants, insects in Texas a snap 2
... available in German . ... have jaws have four fins or limbs, one pair in front ... of evolution, into a marvelous variety of fins, legs, arms, flippers, and ... arrangement of two pairs of appendages? Because we have a belly. ...
... Yale School of Medicine researchers provides insight into how much ... reproductive health. Published in the Jan. 27 issue of ... of reproductive-age women had never discussed their reproductive health with ... provider less than once a year or never. ...
... embryonic stem cells of high clinical quality. It also allows ... The discovery is a big step forward for stem cell ... and thereby curing serious illnesses such as diabetes and Parkinson,s ... from surplus in vitro fertilized (IVF) embryos that are not ...
Cached Biology News:How did we get 4 limbs? Because we have a belly 2How did we get 4 limbs? Because we have a belly 3The science of baby-making still a mystery for many women 2New method increases supply of embryonic stem cells 2
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Polyclonal Antibody to SHPRH...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biotin anti-mouse Ly-49C/F/I/H...
Biology Products: